Aerovate Therapeutics, Inc.
AVTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,650,981 | $20,855,469 | $25,096,036 | $10,072,787 |
| - Cash | $33,751 | $23,491 | $22,397 | $54,197 |
| + Debt | $417 | $675 | $1,090 | $574 |
| Enterprise Value | $2,617,647 | $20,832,653 | $25,074,729 | $10,019,164 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$96 | -$68 | -$15 |
| % Margin | – | – | – | – |
| EBITDA | -$74,314 | -$81,313 | -$53,169 | -$23,007 |
| % Margin | – | – | – | – |
| Net Income | -$69,628 | -$75,521 | -$51,511 | -$22,963 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.44 | -2.87 | -2.1 | -1.87 |
| % Growth | 15% | -36.7% | -12.3% | – |
| Operating Cash Flow | -$71,196 | -$56,778 | -$39,122 | -$27,399 |
| Capital Expenditures | $0 | -$142 | -$195 | -$181 |
| Free Cash Flow | -$71,196 | -$56,920 | -$39,317 | -$27,580 |